Aphios Corporation
- Biotech or pharma, therapeutic R&D
Aphios® Corporation is an emerging growth biotechnology company developing green, patented technology platforms and advanced therapeutics for cancer, infectious diseases (e.g., HIV), and CNS disorders such as Alzheimer’s disease, MS, pain, and opioid addiction. Our hybrid business model includes therapeutic development and technology licensing, supported by 87 patents and $50M in funding, including $20M from NIH. Our scalable structure includes Special Purpose Vehicles (SPVs) and LLCs that drive focused product development and financing through spin-offs like Zindol® (nausea), Amylon™ (Alzheimer’s), Bryolat™ (HIV cure), Aphios® Pharma (cannabinoid drugs), and Aphios® International (pathogen reduction). Exit strategies include licensing, partnerships, M&As, or IPO.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}